NeuroHope Therapeutics

Name

NeuroHope Therapeutics

Legal name

NeuroHope Therapeutics, Inc.

Website

https://neurohopetherapeutics.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Nanopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC), Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)

Keywords

• Nanoparticle drug delivery
• Spinal cord injury therapeutics
• Traumatic brain injury treatments
• Micellar nanotherapeutics
• Central nervous system drug delivery

Headquarters

HQ city

Greenville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Licensing: Pre-revenue biotech company. Future revenue expected through licensing proprietary PgP technology and lead therapeutic candidates to pharmaceutical partners for clinical development and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

NeuroHope Therapeutics develops and seeks to commercialize proprietary polymeric micellar nanotherapeutics (PgP platform) for local, sustained drug delivery to treat central nervous system trauma such as spinal cord injury and traumatic brain injury. Its lead product candidate, Rm-PgP, is a rolipram-loaded PgP nanoparticle administered via intrathecal injection to preserve cAMP levels and reduce secondary injury.

Product overview

NeuroHope Therapeutics is a South Carolina-based biotech startup developing micellar nanotherapeutics for local, sustained drug delivery to treat central nervous system trauma. The company's core product is the PgP polymeric micelle drug delivery system, with its lead candidate being Rm-PgP (rolipram-loaded PgP nanoparticle) for treating spinal cord injury and traumatic brain injury. The PgP platform technology enables delivery of both hydrophobic small molecule drugs and therapeutic nucleic acids (siRNA, mRNA, plasmid DNA, miRNA, antisense oligonucleotides) through local injection, providing prolonged residence time and sustained release at injury sites while avoiding systemic side effects.

Differentiator

Problem solved

Functional benefit

Products and services

• Rm-PgP (Rolipram-loaded PgP Nanoparticle) A micellar nanotherapeutic that loads rolipram (a PDE IV inhibitor) into the proprietary PgP polymeric carrier and is administered via intrathecal injection to provide local, sustained drug release for the treatment of spinal cord injury and traumatic brain injury.
• PgP Polymeric Micelle Drug Delivery System A proprietary amphiphilic graft copolymer (poly lactide-co-glycolide-graft-polyethylenimine) that self-assembles into polymeric micelles for delivering hydrophobic drugs and therapeutic nucleic acids (siRNA, mRNA, plasmid DNA, miRNA, antisense oligonucleotides) to treat central nervous system conditions.

Quantifiable outcome

• Restored cAMP levels up to 7 days with single Rm-PgP intrathecal injection in rat moderate contusion SCI model
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor and core.

• SCbiominorStrategic or Co-development Partner · 1 March 2026Co-Founder Ken Webb participated in 2026 SCbio Annual Conference in Charleston, presenting NeuroHope's drug-delivery technologies for treating central nervous system trauma.
• Clemson UniversitycoreStrategic or Co-development Partner · 1 January 2022Exclusive option license agreement with Clemson University for PgP nanotechnology developed by Dr. Jeoung Soo Lee. The technology originated from Clemson University Bioengineering Department research. This is the core technology platform for NeuroHope's therapeutic development.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Selecta Biosciences: Clinical-stage biotech developing synthetic nanoparticle immunomodulatory and therapeutic platforms (ImmTOR, SEL-302). Comparable as a polymeric nanoparticle platform biotech developing targeted therapeutics.
• Kringle Pharma: Japan-listed biotech developing recombinant human HGF (KP-100IT) for acute spinal cord injury. Comparable as a SCI-specialty biotech with an investigational therapeutic targeting secondary injury pathways.
• Nanobiotix: Clinical-stage nanomedicine company developing novel nano-based therapeutics, including applications in oncology and CNS. Comparable as a nanotherapeutic platform company advancing pipeline assets through clinical development.
• NanoCarrier: Japan-based nanomedicine company developing polymeric micelle and nanoparticle drug delivery systems for oncology and CNS indications. Comparable as a polymeric nanoparticle platform biotech with CNS focus.
• BioAxone BioSciences: Clinical-stage biotech developing therapeutics for spinal cord injury and CNS trauma (e.g., BA-210/Cethrin rho-inhibitor program). Highly comparable to NeuroHope given its SCI focus, CNS trauma indication, and small-cap biotech profile.
• InVivo Therapeutics: Spinal cord injury-focused biotech developing biomaterial and drug-delivery approaches (Neuro-Spinal Scaffold). Direct comparator on indication, stage of development, and SCI-targeted mechanism.

Broad incumbents

• Acorda Therapeutics: Established CNS specialty pharma with approved therapies and pipeline assets in spinal cord injury and neurodegenerative disease. Comparable as an established CNS-trauma/neurodegeneration commercial-stage peer.
• Medicinova: Clinical-stage CNS specialty pharma with MN-166 (ibudilast) in development across neurodegenerative and neurotraumatic indications including SCI and TBI. Comparable as a broader CNS/neurotrauma franchise player.
• Axsome Therapeutics: CNS-focused commercial-stage pharma developing therapeutics across neurology and psychiatry indications. Comparable as a CNS specialty pharmaceutical company pursuing differentiated mechanisms in underserved neurological conditions.
• Alnylam Pharmaceuticals: Commercial-stage RNAi therapeutics company with CNS-pipeline programs leveraging siRNA delivery technology. Comparable as a nucleic-acid-delivery therapeutics company exploring CNS indications, useful benchmark for the nucleic-acid leg of the PgP platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroHope Therapeutics